Search Results

METHODSWe searched the Cochrane Library, MEDLINE, EMBASE, PubMed, Elsevier and CBM databases for randomized placebo-controlled trials of statins published by September 2013, and each trial enrolled at least 100 participants with follow-up for at least 4 weeks. Two reviewers independently assessed the quality of the included studies and extracted the relevant data for analysis using Stata 12.0 software.

RESULTSSixteen trails involving a total of 48973 patients were included in our meta-analysis. The results showed that statins significantly reduced the risk of infection (OR=0.93, 95% CI 0.89 to 0.98, P=0.004) compared to placebo but did not significantly lower infection-related mortality (OR=0.96, 95% CI 0.82 to 1.12, P=0.592).

CONCLUSIONStatins can significantly reduce the risk of infection but does not lower infection-related mortality.

Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; therapeutic use ; Infection ; epidemiology ; mortality ; Randomized Controlled Trials as Topic ; Risk Factors

1.Logical thinking on the large dosage of Statin in clinical implication.

2.Views on FDA's withdrawal of strongest warning against using cholesterol-lowering statins during pregnancy.

3.Pharmacogenomics of statin therapy.

4.Clinical benefits and safety of low-level LDL-C in the new era of lipid-lowering.

5.Impact of statins on risk and survival of ovarian cancer.

6.The mechanisms and the role of statins in treating pulmonary hypertension.

7.Effect of statins on occurrence of infection and infection-related mortality: a meta-analysis.

8.Treatment of chronic heart failure with statins: potential advantages and disadvantages.

9.Mechanism by which statins influence insulin signaling pathway.

10.Influence of JUPITER to the current practice for prevention and therapy of coronary heart disease.

Display Mode

Output Records

File Type